MindWalk Reports 52% Revenue Growth, Secures First Recurring AI Platform Contract, Advances Key Drug Pipeline
Summary
MindWalk Holdings Corp. reported strong Q3 fiscal 2026 financial results with 52% year-over-year revenue growth, secured its first recurring LensAI platform contract, and announced significant advancements in its GLP-1, Dengue, and Influenza drug programs.
Key Events
-
Strong Revenue Growth
Q3 revenue increased 52% year-over-year to $4.2 million (CAD), with US revenue doubling, and year-to-date revenue up 45% to $11.4 million (CAD).
-
First Recurring AI Platform Contract
The company secured its first one-year LensAI platform contract with its largest enterprise AI client, marking a strategic shift towards recurring revenue.
-
Significant Pipeline Progress
The GLP-1 program confirmed in vitro receptor activation relative to semaglutide and is advancing with a large pharma collaborator. Dengue and Influenza vaccine programs also reported key milestones.
-
Improved Net Loss
Net loss from continuing operations for Q3 significantly reduced to $3.9 million (CAD) compared to $22.0 million (CAD) in the prior year, which included a $21.2 million impairment.
Analysis
MindWalk Holdings Corp. delivered strong Q3 fiscal 2026 financial results, highlighted by a 52% year-over-year revenue increase and the signing of its first recurring LensAI platform contract, signaling a positive shift in its business model. The company also reported significant progress across its drug development pipeline, including confirmed in vitro activity for its GLP-1 program with a large pharma collaborator, and advancements in its Dengue and Influenza vaccine programs. While the net loss from continuing operations was $3.9 million, this represents a substantial improvement from the prior year's $22.0 million loss (which included a large impairment). The company is also proactively exploring asset-level financing to support its proprietary programs. Although the B cell Llama™ platform launch was previously announced on March 6, 2026, the comprehensive positive updates on revenue, recurring contracts, and pipeline milestones make this a highly important filing for investors.
At the time of this filing, HYFT was trading at $1.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $59.8M. The 52-week trading range was $0.32 to $3.25. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.